Experimental Treatment and Muscular Dystrophy Jamaica Plain MA

Injecting a therapeutic molecule into muscle appears to jump-start the production of a crucial protein that's missing in patients with Duchenne muscular dystrophy, British researchers report. The treatment so far is only applicable to about 13 percent of people with the debilitating and ultimately fatal disease, but scientists are hopeful that similar molecules might expand the treatment to a wider range of patients.

Barron Chiropractic
(617) 524-6325
456B Centre Street
Jamaica Plain, MA

Data Provided by:
Marian H. Putnam, M.D.
(617) 364-6784
36 Maple Street
Hyde Park (Boston), MA
Business
Marian H. Putnam, M.D. Private Practice of Pe
Specialties
Pediatrics
Insurance
Insurance Plans Accepted: All Blue Cross PlansBoston Health NetChildren's Medical Security PlanHealth Care Value ManagementHarvard Pilgrim health CareMass Health which is our state's MedicaidPrivate Health Care SystemsGreat WestPruCareTufts Health PlanCarpenter
Accepts Uninsured Patients: Yes
Emergency Care: Yes

Doctor Information
Primary Hospital: Children's Hospital
Residency Training: St. Raphael's New Haven; Cincinnati Children's
Medical School: Tufts Medical School, 1974
Additional Information
Languages Spoken: English,Afar,French

Data Provided by:
Calliope Fine, MD
(617) 232-4600
55 Pond Ave
Brookline, ME
Business
Boston Ultrasound
Specialties
Radiology

Data Provided by:
Boston Cat Hospital
(617) 266-7877
665 Beacon St
Boston, MA

Data Provided by:
Newton Chiropractic and Wellness Center
(617) 964-3332
345 Boylston St Suite 300
Newton, MA

Data Provided by:
Marian H Putnam MD
(617) 364-6784
36 Maple St
Hyde Park, MA
Specialties
Pediatrics

Data Provided by:
William M McClune
(617) 282-6600
114 Washington St. 
Dorchester, MA
Specialties
Chiropractic
Insurance
Medicare Accepted: No
Workmens Comp Accepted: No
Accepts Uninsured Patients: No
Emergency Care: No


Data Provided by:
Barron Chiropractic
(617) 298-6325
1520 Blue Hill Ave
Mattapan, MA

Data Provided by:
Korb & Associates
(857) 288-5905
400 Commonwealth Ave # 2
Boston, MA

Data Provided by:
Ajay D Wasan, MD
(617) 732-8510
75 Francis St
Boston, MA
Business
Brigham & Women's Hospital Anesthesiology
Specialties
Anesthesiology

Data Provided by:
Data Provided by:

Experimental Treatment and Muscular Dystrophy

Provided By:

TUESDAY, Aug. 25 (HealthDay News) -- Injecting a therapeutic molecule into muscle appears to jump-start the production of a crucial protein that's missing in patients with Duchenne muscular dystrophy, British researchers report.

The treatment so far is only applicable to about 13 percent of people with the debilitating and ultimately fatal disease, but scientists are hopeful that similar molecules might expand the treatment to a wider range of patients.

Duchenne muscular dystrophy affects about one in 3,500 males, and involves a progressive wasting of muscle due to a genetic inability to produce the protein dystrophin, a key component of muscle structure. No treatments are available for the illness, and most of those affected die by age 30.

Recently, molecules called antisense oligonucleotides have shown some promise. These molecules work by "skipping over" portions of the defective gene that would otherwise block dystrophin production.

In their study, published online Aug. 25 in The Lancet Neurology, researchers at the University College London Institute of Child Health selected seven patients for whom a particular oligonucleotide molecule, called AVI-4658, appeared suitable. In these patients, the molecule "skipped" exon 51 -- the portion of the dystrophin-blocking gene that appeared to get in the way of effective dystrophin production.

Injecting the molecule into the muscles of these seven patients resulted in increased dystrophin production in all treated muscles, according to a journal news release. "Intramuscular AVI-4658 was safe and induced the expression of dystrophin locally within treated muscles," the team wrote. "On the basis of these observations, we have initiated a dose-ranging study to assess the safety and efficacy of repeated doses of systemic intravenous AVI-4658."

In a commentary, Annemieke Aartsma-Rus and Gert-Jan van Ommen, from Leiden, the Netherlands, noted that while only about 13 percent of Duchenne muscular dystrophy patients can be expected to be helped by AVI-4658, molecules that skip other exons on the gene could be used, potentially spreading the benefit to more than 70 percent of patients.

More information

Find out more about Duchenne muscular dystrophy at the Muscular Dystrophy Association.

SOURCE: The Lancet Neurology, news release, Aug. 25, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com